A Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension Group 2 - Re-PHIRE

Study identifier:D8330C00003

ClinicalTrials.gov identifier:NCT05737940

EudraCT identifier:N/A

CTIS identifier:2022-502382-25-00

Recruitment Complete

Official Title

A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)

Medical condition

Pulmonary Hypertension (World Health Organization Group 2)

Phase

Phase 2

Healthy volunteers

Study drug

AZD3427, Placebo

Sex

All

Actual Enrollment

260

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 24 Apr 2023

Estimated Primary Completion Date: 15 Jul 2025

Estimated Study Completion Date: 26 Aug 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2025 by AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria

Inclusion Criteria

:
1. Participant must be ≥ 18 years of age inclusive.
2. Participants must have a pre-existing diagnosis of HF, NYHA function class (FC) II to IV, and a pre-existing diagnosis of PH-LHD or likely or intermediate probability of Pulmonary hypertension due to left heart disease (PH-LHD) as per 2022 Pulmonary hypertension due to left heart disease European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines. Participants must be on stable HF standard of care medication, including diuretics.
3. Participants must have a combination of echocardiographic parameters that show intermediate or high probability of PH as per 2022 ESC/ERS guidelines.
4. Participants must have an on-study elevated pulmonary artery pressure from RHC performed as per RHC manual provided by the Sponsor, at Screening Visit 2:
(a) PAWP ≥ 15 mmHg
(b) mPAP ≥ 20 mmHg
5. Minimum body weight of 45 kg (inclusive).
6. Capable and willing of giving signed informed consent.

Exclusion Criteria

1. Diagnosis of PH in World Health Organization (WHO) Group 1, WHO Group 3, WHO Group 4, or WHO Group 5.
2. Historical or current evidence of a clinically significant disease or disorder.
3. Decompensated HF or hospitalisation due to decompensated HF.
4. Any contraindications to RHC.
5. History of hypersensitivity to SC injections or devices.
6. History of hypersensitivity to drugs with a similar chemical structure or class to AZD3427 or any component of AZD3427 drug product, or ongoing clinically important allergy/hypersensitivity.
7. Known lung disease with Forced expiratory volume in the first second (FEV1) < 30% of predicted.
8. Congenital long QT syndrome.
9. Cardiac ventricular arrhythmia which requires treatment. Participants with atrial fibrillation or flutter and controlled ventricular rate are permitted.
10. History of or anticipated heart transplant or ventricular assist device implantation.
11. Any known planned (scheduled) highly invasive Cardiovascular (CV) procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter, valve repair/replacement, aortic aneurysm surgery, etc).
12. Participants who have previously received AZD3427.

Location

Research Site

Warszawa, Poland, 02-005

Location

Research Site

Wien, Austria, 1100

Location

Research Site

Changsha, China, 430033

Location

Research Site

Baltimore, MD, United States, 21287

Location

Research Site

Toyama-shi, Japan, 930-0194

Location

Research Site

Milano, Italy, 20142

Location

Research Site

Gdansk, Poland, 80-952

Location

Research Site

New Haven, CT, United States, 06519

Arms	Assigned Interventions
Experimental: AZD3427 Dose A The participants will receive single dose of AZD3427 Dose A every 2 weeks for 24 weeks from Day 1 to Day 155.	Drug: AZD3427 The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
Experimental: AZD3427 Dose B The participants will receive single dose of AZD3427 Dose B every 2 weeks for 24 weeks from Day 1 to Day 155.	Drug: AZD3427 The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
Experimental: AZD3427 Dose C The participants will receive single dose of AZD3427 Dose C every 2 weeks for 24 weeks from Day 1 to Day 155.	Drug: AZD3427 The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
Placebo Comparator: Placebo The participants will receive single dose of placebo every 2 weeks for 24 weeks from Day 1 to Day 155.	Drug: Placebo The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Trial Results Summaries